Androgens and Antiandrogens Pharmacology

Finasteride is primarily metabolized in the liver, where enzymes convert it into inactive metabolites. Approximately 40-50% of the administered dose is metabolized before being excreted, indicating that a significant portion undergoes biotransformation. This metabolism is crucial for reducing systemic exposure and potential side effects, as the remaining dose is eliminated unchanged in urine and feces. Understanding this metabolic process helps in assessing the drug's efficacy and safety profile.

2-hydroxyflutamide is the active metabolite of flutamide that exerts its effects by competitively blocking androgen receptors. This mechanism is significant in the treatment of prostate cancer, as it inhibits the action of androgens like testosterone, which can promote cancer cell growth. By binding to these receptors, 2-hydroxyflutamide effectively reduces the stimulation of androgen-dependent pathways, thereby helping to control tumor progression. Its specific activity and potency make it a crucial component in the therapeutic efficacy of flutamide.

Flutamide functions as an antiandrogen primarily by competing with testosterone for binding to androgen receptors. This competitive antagonism prevents testosterone from exerting its effects on target tissues, thereby inhibiting androgenic activity. Unlike other mechanisms, such as inhibiting 5α-reductase or aromatase, flutamide directly blocks the receptor's activation, making it effective in conditions like prostate cancer where androgen signaling promotes tumor growth. This targeted action helps reduce the physiological effects of androgens, leading to therapeutic benefits in androgen-dependent diseases.

Terazosin and tamsulosin are selective α1-adrenoceptor antagonists that help relax smooth muscle in the prostate and bladder neck, improving urinary flow in patients with benign prostatic hyperplasia (BPH). Unlike finasteride, which inhibits the conversion of testosterone to dihydrotestosterone, these medications provide symptomatic relief by directly alleviating obstruction. Their effectiveness in reducing urinary symptoms associated with BPH makes them suitable alternatives for patients who may not tolerate or prefer not to use finasteride.

Finasteride and dutasteride are 5-alpha-reductase inhibitors that reduce the conversion of testosterone to dihydrotestosterone (DHT), a hormone that contributes to prostate growth. By lowering DHT levels, these medications help alleviate symptoms associated with benign prostatic hyperplasia (BPH), such as urinary obstruction and increased frequency of urination. They are not primarily indicated for metastatic prostate cancer, hypogonadism, or polycystic ovary syndrome, making their primary clinical use the treatment of symptomatic BPH.

Testosterone is converted to dihydrotestosterone (DHT) primarily by the enzyme 5α-reductase. This enzyme catalyzes the reduction of the double bond in the testosterone molecule, resulting in the formation of DHT, which is a more potent androgen. DHT plays a crucial role in various physiological processes, including the development of male characteristics and the functioning of the prostate gland. The other enzymes listed, such as P450 aromatase, primarily convert testosterone to estradiol, while adenylyl cyclase and phospholipase C are involved in different signaling pathways and do not participate in this conversion.

Finasteride, a medication commonly used for conditions like benign prostatic hyperplasia and male pattern baldness, has a half-life of about 7 hours following oral administration. This means that it takes approximately 7 hours for the body to reduce the concentration of the drug in the bloodstream by half. Understanding the half-life is crucial for determining dosing schedules and ensuring therapeutic effectiveness while minimizing side effects.

Finasteride primarily works by inhibiting the enzyme 5α-reductase, which is responsible for converting testosterone into dihydrotestosterone (DHT). DHT is a potent androgen that contributes to conditions such as benign prostatic hyperplasia and androgenetic alopecia. By reducing DHT levels, finasteride effectively diminishes the androgenic effects associated with these conditions, helping to alleviate symptoms and promote hair regrowth in affected individuals. This mechanism distinguishes finasteride from other antiandrogen strategies, such as blocking androgen receptors or affecting hormone release.

Prolonged use of androgens can lead to significant liver damage, including the development of liver tumors. Adenocarcinoma of the liver is a serious adverse effect associated with long-term androgen therapy, as these substances can promote hepatic cellular proliferation and alter liver metabolism. Chronic exposure to androgens may increase the risk of neoplastic changes in liver cells, leading to malignancies such as adenocarcinoma. This underscores the importance of monitoring liver function and potential complications in patients undergoing androgen treatment.

Androgens can lead to premature fusion of epiphyses in children, which occurs when the growth plates in long bones close earlier than normal. This fusion limits further growth in height, as it effectively ends the period during which bones can elongate. While androgens influence other growth-related factors, such as growth hormone and IGF-1, their most significant impact on linear growth is through this mechanism, resulting in a shorter adult stature if exposure occurs before the completion of skeletal growth.

Supraphysiologic doses of androgens can lead to negative feedback on the hypothalamic-pituitary-gonadal axis. This results in decreased secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which are crucial for stimulating testicular function. Consequently, the testes may shrink in size, and sperm production can be severely impaired, leading to azoospermia. The excess androgens disrupt the normal hormonal balance, ultimately harming male reproductive capabilities.

Gynaecomastia associated with androgen use primarily occurs due to the conversion of testosterone into estrogens through aromatization. This process increases estrogen levels in the body, which can stimulate breast tissue growth, leading to gynaecomastia. While testosterone itself can exert some effects, the elevation of estrogen is a more significant factor in the development of breast tissue in this context. Thus, the peripheral conversion of testosterone to estrogens is the key mechanism behind this condition.

Androgens can cause sodium and water retention, which may exacerbate fluid overload in patients with congestive heart failure (CHF). In CHF, the heart's ability to pump blood effectively is compromised, leading to fluid accumulation in tissues. The use of androgens in such patients can worsen their condition by increasing blood volume and pressure, potentially resulting in symptoms like edema and shortness of breath. Therefore, careful monitoring and cautious use of androgens are essential in individuals with CHF to avoid these adverse effects.

Androgens, such as testosterone, can influence fetal development, particularly in female embryos. When administered during pregnancy, they can lead to virilization, resulting in the masculinization of female fetuses. This can manifest as ambiguous genitalia or other male characteristics, which poses significant ethical and medical concerns. Therefore, the use of androgens is contraindicated to prevent these adverse developmental effects on female fetuses.

About 90% of endogenous testosterone is metabolized and eliminated from the body. This high percentage reflects the body's efficient processing of hormones, where testosterone undergoes conversion into various metabolites through enzymatic actions in the liver and other tissues. These metabolites are then excreted primarily through urine. This extensive metabolism is crucial for regulating testosterone levels and ensuring that excess hormone does not accumulate, maintaining hormonal balance and overall physiological function.

Aromatase (P450 aromatase) is an enzyme that facilitates the conversion of androgens, such as testosterone, into estrogens, including estradiol. This process primarily occurs in adipose tissue, the liver, and the hypothalamus. Aromatase plays a crucial role in regulating estrogen levels in both males and females, influencing various physiological processes. In contrast, the other enzymes listed are involved in different aspects of steroid metabolism, such as the reduction or interconversion of steroids, but do not catalyze the specific conversion of testosterone to estradiol.

When testosterone is metabolized in the liver, it is converted into androstenedione, a steroid hormone that serves as a precursor to both testosterone and estrogen. Androstenedione has weak androgenic activity compared to testosterone but can still influence various physiological processes in the body. This conversion is part of the body's way of regulating hormone levels and maintaining balance between androgens and estrogens.

Free testosterone has a relatively short elimination half-life due to its rapid metabolism and clearance from the bloodstream. After being released into circulation, it is quickly inactivated and excreted, primarily through the liver and kidneys. This brief half-life of 10–20 minutes reflects the hormone's dynamic nature in the body, allowing for swift physiological responses while also necessitating regular production to maintain adequate levels for biological functions.

Testosterone primarily binds to sex steroid-binding globulin (SHBG) in circulation, which is a specific carrier protein for sex hormones. SHBG regulates the bioavailability of testosterone, influencing its effects on target tissues. While albumin can also bind testosterone, SHBG has a higher affinity, making it the principal transport protein for testosterone in the bloodstream. This binding is crucial for maintaining hormonal balance and regulating the physiological actions of testosterone in the body.

Testosterone and dihydrotestosterone (DHT) are steroid hormones that pass through the cell membrane and bind to specific nuclear receptors in the cytoplasm or nucleus. This hormone-receptor complex then interacts with DNA, influencing the transcription of target genes. This mechanism allows them to regulate various physiological processes, including development, metabolism, and reproductive functions, by altering the expression of genes in a cell-specific manner.